A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial

2012127 citationsJournal Article

Authors

Twelve months' treatment with doxycycline or rifampin, alone or in combination, has no beneficial effects on cognition or function in AD.

Good health and well-being

Published in: International Journal of Geriatric Psychiatry

Volume 28, Issue 5, pp. 463-470

Field-Weighted Citation Impact: 1.52